Lunai Bioworks (LNAI) Non Operating Income (2014 - 2026)
Lunai Bioworks (LNAI) posted quarterly Non Operating Income of -$1.1 million for Q1 2026, down 126.29% year-over-year from $4.4 million in Q1 2025, and down 4865.24% quarter-over-quarter from $24010.0 in Q4 2025.
Lunai Bioworks (LNAI) Non Operating Income (2014 - 2026) Analysis & Trends
Lunai Bioworks' Non Operating Income history runs 13 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 126.29% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $5.2 million (down 57.24% YoY), while the FY2025 annual figure was $11.0 million, up 261.47% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1.1 million, down from $24010.0 in the prior quarter.
- The five-year high for Non Operating Income was $9.1 million in Q3 2024, with the low at -$7.6 million in Q1 2024.
- The 5-year median for Non Operating Income is -$142571.0 (2023), against an average of $822331.0.
- Peak annual rise in Non Operating Income reached 3237.19% in 2024, while the deepest fall reached 5237.15% in 2024.
- Lunai Bioworks' Non Operating Income stood at -$89882.0 in 2022, then plunged by 188.21% to -$259046.0 in 2023, then tumbled by 944.63% to -$2.7 million in 2024, then soared by 100.89% to $24010.0 in 2025, then tumbled by 4865.24% to -$1.1 million in 2026.
- Business Quant data shows LNAI's Non Operating Income at -$1.1 million in Q1 2026, $24010.0 in Q4 2025, and $6.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | -1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | 24,010.00 |
| Sep 30, 2025 | 6.13 Mn |
| Jun 30, 2025 | 186,405.00 |
| Mar 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Sep 30, 2024 | 9.13 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | -7.61 Mn |
| Dec 31, 2023 | -259,046.00 |
| Sep 30, 2023 | -290,914.00 |
| Jun 30, 2023 | -263,279.00 |
| Mar 31, 2023 | -142,571.00 |
| Dec 31, 2022 | -89,882.00 |
| Sep 30, 2022 | -509,144.00 |
| Jun 30, 2022 | 7.97 Mn |
| Mar 31, 2022 | -2.17 Mn |
| Dec 31, 2021 | -252,150.00 |
| Sep 30, 2021 | -2.91 Mn |
| Jun 30, 2021 | -3.18 Mn |